kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Aurora A protein kinase inhibitor MLN 8237, 5 mg  

Aurora A protein kinase inhibitor MLN 8237, 5 mg

4-(9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[e]pyrimido[5,4-c]azepin-2-ylamino)-2-methoxybenzoic acid

MLN 8237 is a second generation and highly selective aurora A protein kinase inhibitor
Synonyms: Alisertib

More details


Availability: within 3 days

156,00 €

Background: MLN 8237 is a second generation, orally bioavailable, potent and highly selective aurora A protein kinase inhibitor.

Chemical formula: C27H20ClFN4O4
Molecular weight: 518.92 g/mol
Purity: 99 %
Appearance: Yellow solid
Solubility: Soluble in 0.1N NaOH(aq) and DMSO
CAS Number: 1028486-01-2

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers. 


DA Sloane et al. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem. Biol. 2010, 5(6), 563-576.
G Görgün et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010, 115(25), 5202-5213.
M Tomita, N Mori. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro. Cancer Sci. 2010, 101(5), 1204-1211. 
MG Manfredi et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res. 2011, 17(24), 7614-7624.

The following products could also be interesting for you: